Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study

Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study

V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult pneumococcal disease after the introduction of pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly prevalent in adult invasive pneumococcal disease (I...

Full description

Bibliographic Details
Main Authors: Miwa Haranaka, Makoto Yono, Hiroyuki Kishino, Rie Igarashi, Nobuyuki Oshima, Miyuki Sawata, Heather Loryn Platt
Format: Article
Language:English
Published: Taylor & Francis Group 2023-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
v116
immunogenicity
pneumococcal conjugate vaccine
safety
tolerability
pneumococcal disease
japanese
adults
21-valent
Online Access:http://dx.doi.org/10.1080/21645515.2023.2228162

Internet

http://dx.doi.org/10.1080/21645515.2023.2228162

Similar Items